Time of up-dosing Up to peak GPS After peak GPS Total
Total number of patients, N 198 52 250
Median age range), years 26.5 (6-73) 29.5 (5-50) 27.0 (5-73)
Gender, N (%)      
males 101 (51.0%) 23 (44.2%) 124 (49.6%)
females 97 (49.0%) 29 (55.8%) 126 (50.4%)
Duration since diagnosis of grass pollen allergy, mean ± SD, years 3.2 ± 5.4 5.5 ± 9.7 3.7 ± 6.6
Patients with moderate to severe symptoms, N (%)      
Nasal symptoms 183 (92.4%) 49 (94.3%) 232 (92.8%)
Eye symptoms 163 (82.3%) 42 (80.8%) 205 (82.0%)
Patients withknown concomitant allergies, N (%) 116 (60.1%) 38 (74.5%) 154 (63.1%)
tree pollen 82 (41.4%) 23 (44.2%) 105 (42.0%)
house dust mites 43 (21.7%) 17 (32.7%) 60 (24.0%)
animal epithelia 38 (19.2%) 11 (21.2%) 49 (19.6%)
Patients with asthma, N (%) 43 (21.7%) 10 (19.2%) 53 (21.2%)
Patients first treated with SIT, N (%) 176 (88.9%) 43 (82.7%) 219 (87.6%)
Patients who used symptomatic drugs in previous GPS 168 (84.8%) 44 (84.6%) 212 (84.8%)
Table 1: Patient characteristics stratified for patients who started treatment up to the peak of the grass pollen season (‘up to peak GPS’) or after the end of the grass pollen season (‘after peak GPS’).
Goto home»